Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Variability in clinical response to standard therapeutic dosage regimen was reported in the 1950s by many pioneers in the field. Since then, the association between monogenic polymorphisms and variations of drugs’ metabolism, transport, or target had been identified and the vision of personalized drug therapy in health care envisioned [1, 2]. Pharmacogenomic-guided drug therapy for patient is based on the premise that a large portion of interindividual variability in drug response (efficacy and/or toxicity) is genetically determined. Despite the widespread recognition of the scientific rationale and the clinical implementation of pharmacogenomic tests at several major academic medical institutions [3-7], most clinicians and researchers engaged in the discipline would agree that the early vision of achieving personalized therapy in the form of therapeutic regimens tailored to an individual’s genetic profile remains some years away.

Original languageEnglish (US)
Title of host publicationOmics in Clinical Practice
Subtitle of host publicationGenomics, Pharmacogenomics, Proteomics, and Transcriptomics in Clinical Research
PublisherApple Academic Press
Pages95-133
Number of pages39
ISBN (Electronic)9781482262438
ISBN (Print)9781771880602
DOIs
StatePublished - Jan 1 2014

Fingerprint

Drug therapy
Pharmacogenetics
Polymorphism
Health care
Metabolism
Pharmaceutical Preparations
Toxicity
Drug Therapy
Therapeutics
Research Personnel
Delivery of Health Care

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Lam, Y. F. (2014). Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice. In Omics in Clinical Practice: Genomics, Pharmacogenomics, Proteomics, and Transcriptomics in Clinical Research (pp. 95-133). Apple Academic Press. https://doi.org/10.1201/b17137

Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice. / Lam, Yui-wing F.

Omics in Clinical Practice: Genomics, Pharmacogenomics, Proteomics, and Transcriptomics in Clinical Research. Apple Academic Press, 2014. p. 95-133.

Research output: Chapter in Book/Report/Conference proceedingChapter

Lam, YF 2014, Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice. in Omics in Clinical Practice: Genomics, Pharmacogenomics, Proteomics, and Transcriptomics in Clinical Research. Apple Academic Press, pp. 95-133. https://doi.org/10.1201/b17137
Lam YF. Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice. In Omics in Clinical Practice: Genomics, Pharmacogenomics, Proteomics, and Transcriptomics in Clinical Research. Apple Academic Press. 2014. p. 95-133 https://doi.org/10.1201/b17137
Lam, Yui-wing F. / Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice. Omics in Clinical Practice: Genomics, Pharmacogenomics, Proteomics, and Transcriptomics in Clinical Research. Apple Academic Press, 2014. pp. 95-133
@inbook{15082f287665418ea6667ac317ea23ba,
title = "Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice",
abstract = "Variability in clinical response to standard therapeutic dosage regimen was reported in the 1950s by many pioneers in the field. Since then, the association between monogenic polymorphisms and variations of drugs’ metabolism, transport, or target had been identified and the vision of personalized drug therapy in health care envisioned [1, 2]. Pharmacogenomic-guided drug therapy for patient is based on the premise that a large portion of interindividual variability in drug response (efficacy and/or toxicity) is genetically determined. Despite the widespread recognition of the scientific rationale and the clinical implementation of pharmacogenomic tests at several major academic medical institutions [3-7], most clinicians and researchers engaged in the discipline would agree that the early vision of achieving personalized therapy in the form of therapeutic regimens tailored to an individual’s genetic profile remains some years away.",
author = "Lam, {Yui-wing F}",
year = "2014",
month = "1",
day = "1",
doi = "10.1201/b17137",
language = "English (US)",
isbn = "9781771880602",
pages = "95--133",
booktitle = "Omics in Clinical Practice",
publisher = "Apple Academic Press",

}

TY - CHAP

T1 - Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice

AU - Lam, Yui-wing F

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Variability in clinical response to standard therapeutic dosage regimen was reported in the 1950s by many pioneers in the field. Since then, the association between monogenic polymorphisms and variations of drugs’ metabolism, transport, or target had been identified and the vision of personalized drug therapy in health care envisioned [1, 2]. Pharmacogenomic-guided drug therapy for patient is based on the premise that a large portion of interindividual variability in drug response (efficacy and/or toxicity) is genetically determined. Despite the widespread recognition of the scientific rationale and the clinical implementation of pharmacogenomic tests at several major academic medical institutions [3-7], most clinicians and researchers engaged in the discipline would agree that the early vision of achieving personalized therapy in the form of therapeutic regimens tailored to an individual’s genetic profile remains some years away.

AB - Variability in clinical response to standard therapeutic dosage regimen was reported in the 1950s by many pioneers in the field. Since then, the association between monogenic polymorphisms and variations of drugs’ metabolism, transport, or target had been identified and the vision of personalized drug therapy in health care envisioned [1, 2]. Pharmacogenomic-guided drug therapy for patient is based on the premise that a large portion of interindividual variability in drug response (efficacy and/or toxicity) is genetically determined. Despite the widespread recognition of the scientific rationale and the clinical implementation of pharmacogenomic tests at several major academic medical institutions [3-7], most clinicians and researchers engaged in the discipline would agree that the early vision of achieving personalized therapy in the form of therapeutic regimens tailored to an individual’s genetic profile remains some years away.

UR - http://www.scopus.com/inward/record.url?scp=85054277358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054277358&partnerID=8YFLogxK

U2 - 10.1201/b17137

DO - 10.1201/b17137

M3 - Chapter

AN - SCOPUS:85054277358

SN - 9781771880602

SP - 95

EP - 133

BT - Omics in Clinical Practice

PB - Apple Academic Press

ER -